Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2010-6-1
pubmed:abstractText
Allergen-specific immunotherapy (SIT) is the only available potentially curative approach in the management of allergic diseases. Therapies that boost regulatory T cell induction during SIT might further enhance its effectiveness.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1097-6825
pubmed:author
pubmed:copyrightInfo
Copyright (c) 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
125
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1220-7
pubmed:dateRevised
2011-1-24
pubmed:meshHeading
pubmed-meshheading:20434204-Acetates, pubmed-meshheading:20434204-Administration, Inhalation, pubmed-meshheading:20434204-Animals, pubmed-meshheading:20434204-Anti-Asthmatic Agents, pubmed-meshheading:20434204-Antigens, Dermatophagoides, pubmed-meshheading:20434204-Asthma, pubmed-meshheading:20434204-Budesonide, pubmed-meshheading:20434204-Chemotherapy, Adjuvant, pubmed-meshheading:20434204-Child, pubmed-meshheading:20434204-Desensitization, Immunologic, pubmed-meshheading:20434204-Double-Blind Method, pubmed-meshheading:20434204-Follow-Up Studies, pubmed-meshheading:20434204-Humans, pubmed-meshheading:20434204-Lymphocyte Activation, pubmed-meshheading:20434204-Pyroglyphidae, pubmed-meshheading:20434204-Quinolines, pubmed-meshheading:20434204-T-Lymphocytes, Regulatory, pubmed-meshheading:20434204-Time Factors
pubmed:year
2010
pubmed:articleTitle
Montelukast treatment may alter the early efficacy of immunotherapy in children with asthma.
pubmed:affiliation
Department of Pediatrics and Allergy, Medical University of Lodz, Lodz, Poland.
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't